Lebrikizumab for moderate-to-severe eczema
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests an injectable drug called lebrikizumab for people with moderate-to-severe eczema (atopic dermatitis) that has not been well controlled with topical treatments. It may help reduce skin symptoms and itching.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had eczema for at least 1 year and creams or ointments haven't worked well enough or aren't recommended.
- Your eczema covers more than 10% of your body and is rated as moderate or severe by a doctor.
- You have not used any biologic drugs (like dupilumab) for eczema before.
- You have not used prescription moisturizers or certain eczema creams within the past week.
- You are willing to avoid pregnancy or use effective birth control during the study and for 17 weeks after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies whether lebrikizumab is safe and continues to work over the long term for children and teens with moderate-to-severe atopic dermatitis (eczema). It’s meant for people who already finished a related earlier study and can safely continue.
This study looks at how lebrikizumab (Ebglyss) affects daily life and skin symptoms in adults with moderate-to-severe eczema. You may join if your doctor has prescribed this medication as part of your regular care.
This trial tests a new injectable drug called SKB575 for people with moderate to severe atopic dermatitis (eczema). It aims to see how safe and effective the drug is, especially for those who haven't had success with strong creams or pills.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This trial tests a new drug called IBI3002 in people with moderate-to-severe atopic dermatitis (eczema) to see if it is safe and tolerable. It may help reduce skin inflammation and itching.
This study tests a new medication called IBI356 for people with moderate to severe eczema that hasn't improved with standard creams. The goal is to see if this medicine can safely reduce the redness, itching, and rash.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.